Trial Information

Summary: Evaluating therapies for patients with Type 2 Diabetes

A 24-Week Randomized, Double-Blind, Multi-Center, Placebo Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy when Added to the Therapy of Patients with Type 2 Diabetes Poorly.

For more information,

Contact:

Sheila Hirsch
Horizon Institute for Clinical Research
3990 Sheridan St, Suite 210
Hollywood, FL 33021
Telephone: 954-964-6881
Fax: 954 962-5826
Email:

Profile Page: Horizon Institute for Clinical Research, Hollywood, FL

If you would like to learn more about participating in this study, please send an e-mail message using the form below.

*Subject:

Name:

Address:

City:

State:

*Zip:

*Country:

Phone:

*Email address:

Message:

Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 5:44:49 AM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA